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Abstract
Background: The aim was to evaluate cancer-specific survival (CSS) and overall survival (OS) in patients with
prostate cancer (PCa) recurrence who underwent salvage extended pelvic lymph node dissection (ePLND), taking
into consideration pre- and postoperative androgen deprivation therapy (ADT).
Methods: Salvage ePLND was performed in a cohort of 54 patients with PCa recurrence, and data from 45 patients
were analyzed. The indications for salvage ePLND were biochemical recurrence (BCR) of PCa and suspect findings
on 11C-choline PET/CT. PSA-level, biochemical response (BR), duration of biochemical recurrence freedom (BCRF),
number of metastases, OS and CSS were analyzed retrospectively.
Results: The average follow-up was 42.7 ± 20.8 months. Thirty-three patients (73.3 %, 95 % CI: 60.5–83.6 %)
achieved BCRF during follow-up. The mean BCRF-period was 31.4 ± 19.7 months. CSS and OS were both 91.7 % ± 4.
8 % (3-year survival) and 80.6 ± 8.6 % (5-year survival). Twenty-four patients (53.3 %, 95 % CI: 40.0–66.3 %) with
castration-resistant PCa (CRPC) responded again to ADT after salvage ePLND.
Conclusions: Salvage ePLND for selected patients with BCR and clinically recurrent nodal disease can achieve an
immediate complete PSA response (i. e. BCRF) in nearly half of the patients. Patients with CRPC responded again to
ADT after ePLND. Multicenter prospective studies with a control group are needed.
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survival
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Background
The standard treatment options for patients with pros-
tate cancer (PCa) recurrence after radical prostatectomy
(RP) are radiotherapy (RT) and/or androgen deprivation
therapy (ADT) [1, 2]. Salvage extended pelvic lymph
node dissection (ePLND) is neither mentioned in the
European Association of Urology (EAU) guidelines, nor
in the German S-3 and the US guidelines. However, it
might be an alternative treatment approach in a selected
group of the patients. Moreover, our data show that pa-
tients who had ceased to respond to ADT (i. e. CRPC
patients) responded again to ADT after salvage ePLND.
RT is the most common option in cases of pelvic PCa
recurrence. Salvage RT should be offered to patients
with biochemical recurrence (BCR) or local recurrence
after RP if there is no evidence of distant metastatic dis-
ease [3]. Briganti et al. performed a multicenter retro-
spective analysis of 472 node-negative patients who
experienced BCR after RP and received salvage RT. The
rate of 5-year BCR-free survival after early salvage RT
was 73.4 %. The authors have developed the first nomo-
gram to predict the outcome after salvage RT [4].
ADT is a standard method in node-positive patients
with BCR after primary RP and RT [5]. Intermittent an-
drogen deprivation results in non-inferior oncological
efficacy when compared with continuous ADT in well-
selected populations [2].
Sciarra et al. showed that 29.7 % of the patients with
BCR after RP who received intermittent ADT developed
castration-resistant prostate cancer (CRPC) and 14.2 %
of the cases showed clinical progression, with a mean
duration of 88.4 ± 14.3 months and 106.5 ± 20.6 months,
respectively [6]. Prolonged ADT exposure increases the
risk of cardiovascular disease and diabetes in men aged
>75 years with PCa [7].
New substances such as abiraterone and enzalutamide
represent new therapeutic options. Their mechanism of
action regarding renewed ADT response is not clear, es-
pecially in consideration of insufficient control possibil-
ities. In one-third of patients receiving abiraterone, the
PSA level showed no tendency to decrease [8].
An alternative treatment option for patients with re-
current PCa, especially in CRPC, is salvage ePLND. The
effect of the salvage surgery on the response to ADT
after surgery is not clear. In the past 5 years there has
been an increase in publications on the outcomes of sal-
vage PLND. There is a partial or even a complete PSA
response to salvage LND in patients with nodal recur-
rence of PCa. Despite the relatively small patient num-
bers and the lack of a long-term follow-up, the available
data mark a preliminary success and demonstrate this
technique to be a promising new approach [9–11].
The data presented in these and other similar studies
were collected and analyzed in different centers and
published independently of each other, but the outcome
of all these studies was surprisingly similar. Salvage
ePLND can take a more significant place in the treat-
ment of patients with BCR. Some authors point out that
a more extended type of PLND at the time of primary
RP is to be favored. A high percentage of patients with
pelvic LN recurrence responded with reduced PSA after
salvage surgery, and thus, they might have already bene-
fited from more extensive PLND during primary surgery
[9, 10, 12].
In this single center retrospective study, we analyzed
CSS and overall survival (OS) data, as well as the influ-
ence of salvage surgery on the response to ADT in pa-
tients with previous CRPC. This evaluation provides us
with sufficient preliminary evidence to initiate a further
study or to join a similar study with prospective ran-
domized design.
Methods
We analyzed a cohort of 54 patients with PCa recur-
rence. Most of the patients visited our clinic on their
own initiative. They had expressed a wish to be treated
in an alternative surgical way. All patients were informed
about the absence of prospective multicenter data and
about the fact that salvage ePLND is not mentioned in
US, European or S3 guidelines.
All patients gave signed informed consent. Thirteen
patients [28.9 %, 95 % confidence interval (CI): 18.2–
41.9 %] were aged >70 years at the time of salvage
ePLND. Recurrence was defined as an increase of PSA
>0.5 ng/ml. We introduced salvage ePLND in Kiel in
November 2003. We could eventually only evaluate the
data from 45 of 54 patients, as the other patients contin-
ued follow-up treatment at their local urologist and we
were unable to collect their data. The mean follow-up
period was 42.7 ± 20.8 months.
Preoperatively, all patients underwent positron emis-
sion tomography (PET)/computed tomography (CT) im-
aging. ADT was aborted at least 4 weeks prior to PET/
CT examination. There was no bone metastasis prior to
salvage ePLND. The indications for salvage ePLND were
BCR and/or positive PET/CT scan. Salvage ePLND was
done in thirteen patients (37.1 %), who had undergone
primary RP without LND; some of these had a negative
PET/CT scan result, but all had a proven BCR.
We used the D’Amico risk classification to describe a
primary tumor (Table 1). We defined an initial PSA level
(iPSA) as a PSA level prior to primary treatment. Ten of
45 patients (22.2 %) had RT as primary treatment and
underwent RP during salvage ePLND as well. Thirteen
patients (28.9 %) had primary RP without any LND. In
22 patients (48.9 %) with primary LND, the mean num-
ber of removed LNs was 13.3 (range: 3–26) and LN me-
tastases were found in five of those patients. R1 stage
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after primary prostatectomy were diagnosed in 12
(34.3 %) out of 35 patients. Gleason score (GS) sub-
groups were as follows: four (8.9 %) patients had GS 6;
17 (37.8 %) had GS 7; 10 (22.2 %) had GS 8; 10 (22.2 %)
had GS 9; and two (4.4 %) had GS 10; and two (4.4 %)
patients had a non-detectable GS (Table 1). Most pa-
tients had undergone primary RP ex domo.
We performed salvage ePLND according to the surgi-
cal template developed at our department [13]. The sur-
gical regions of the Kiel template are defined as follows:
(1) para-aortic LNs; (2) LNs along the common iliac ar-
tery; (3) LNs along the external iliac artery; (4) LNs
along the internal iliac artery; (5) LNs in the Marcille’s
triangle; (6) obturator LNs; and (7) presacral LNs. The
Kiel principles of salvage ePLND are: (1) exclusively
transperitoneal access; (2) definition of landmarks such
as the iliac vessels prior to LND; and (3) careful separ-
ation of the ureter from the surrounding tissue. Subse-
quent to these measures, LND is systematically
performed from the top downwards. Small or medium
clips are used to avoid extensive ligation. Moreover, we
used a harmonic scalpel to seal the lymph vessels and
shorten the operation time [14]. The operation was per-
formed no later than 4 months after PET/CT. None of
the patients had bone metastases at the time of the
intervention. The removed LNs were cut into 4-mm
slices and examined further at our Pathology Institute.
PSA measurements were performed 40 days after sur-
gery and thereafter every 3–6 months. In case of bio-
chemical progression, PET/CT and bone scintigraphy
were performed to exclude clinical progression. The data
on the occurrence of bone metastases have been pre-
sented in our paper. There was no standard protocol for
postoperative imaging diagnostics.
BR was defined as PSA regression immediately after
salvage surgery, measured 40 days after surgery, regard-
less of whether the level was above or under BCR cri-
teria. Some patients received ADT directly after salvage
ePLND, prescribed by the local urologist. The patients
who were followed up in our department received ADT
on occurrence of renewed BCR after salvage ePLND.
These patients have continuously received complete an-
drogen blockage.
We analyzed the number of removed LNs, number of
positive LNs, changes in PSA level, CSS and OS. Key
points in the clinical outcome of salvage ePLND were
BCR-free survival and its duration, as well as CSS and
OS, taking into consideration the administration of ADT
and the occurrence of bone metastases during follow-
up. On analyzing the data, we found out that 80 % of
the patients who underwent salvage ePLND had shown
castration resistance (CRPC) prior to surgery, although
CRPC was not a primary indication criterion for salvage
surgery. We analysed the influence (whether negative or
positive) of salvage ePLND +ADT on PSA recurrence
after salvage ePLND in these particular patients.
95 % CIs for frequencies were determined based on
the binomial distribution, with p = 0.05. Statistically sig-
nificant differences of frequencies were determined by
the exact variant of criterion χ2. Risk factors affecting
survival were determined using Cox regression. CSS and
OS were determined using Kaplan-Meier analysis.
The research was performed with the approval of the
appropriate ethics committee (Ethics Commission, Fac-
ulty of Medicine, CAU Kiel University, reference number
– D474/15).
Results
The patient data are listed in Table 2 and Figs. 1, 2, 3
and 4. The PSA was measured ca. 40 days after salvage
ePLND. At this point, 22 patients (48.9 %, 95 % CI:
35.8–62.1 %) were BCR-free. 16 of 22 patients (72.7 %)
with immediate complete BR after salvage ePLND were
treated with ADT prior to surgery. During follow-up, 33
patients (73.3 %, 95 % CI: 60.5–83.6 %) achieved
Table 1 Summary of results of initial treatment (n = 35 with
initial RP and n = 10 with initial RT, summary n = 45)
Total number of evaluated patients 45 100 %
Initial RT (%) 10 22.2 %
Initial RP without LND (%) 13 28.9 %
Initial RP with LND (%) 22 48.9 %
Average number of removed LN´s (n = 22) 13.3 3-26
Average number of N1 (%) 5 22.7 %
Mean iPSA, ng/ml (SD) 6.7 ±1.6
Risk classificationa
Low (%) 1 2.2 %
Intermediate (%) 21 46.7 %
High (%) 21 46.7 %
T stage after RP
T2 (%) 15 33.3 %
T3 (%) 27 60.0 %
T3a (%) 12 26.7 %
T3b (%) 15 33.3 %
Tx (%) 3 6.7 %
Gleason Score after RPGS 6 (%)
GS 7 (%) 4 8.9 %
GS 8 (%) 17 37.8 %
GS 9 (%) 10 22.2 %
GS 10 (%) 10 22.2 %
GSx (non detectable) (%) 2 4.4 %
2 4.4 %
R1 after initial PR (out of 35 patients) (%) 12 34.3 %
aIn two patients, the initial risk group was unknown
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BCR-freedom (BCRF), including those who received and
responded to ADT again (Fig. 1) The mean follow-up in
these 33 patients is 46.7 ± 25.0 months (median follow-up
47 months). In 10 patients (22.2 %, 95 % CI: 12.9–34.6 %),
bone metastases appeared during follow-up. The mean
duration until diagnosis of bone metastases was 25.9 ±
18.4 (median 21.5 months). Seven patients (15.6 %,
95 % CI: 8.0–26.8 %) died and six of these had bone me-
tastases. In these patients, the average follow-up between
salvage ePLND and occurrence of bone metastases was
34.2 ± 9.5 months [in this and similar cases, the data are
represented as mean ± standard deviation (SD)]. BCR-free
survival in patients with and without bone metastases was
dramatically different (Fig. 2).
It is notable that the mean iPSA in patients without
bone metastases was 5.5 ng/ml compared with 29.1 ng/
ml in those with postoperatively diagnosed bone metas-
tases. The mean PSA nadir after salvage ePLND was
4.7 ng/ml. We used an interval of 40 days for PSA nadir.
CSS and OS were equal at 91.7 ± 4.8 % (3-year CSS and
OS) and 80.6 ± 8.6 % (5-year CSS and OS) (Figs. 3 and 4).
A total of 971 LNs were removed during 45 salvage
ePLNDs, with a mean of 21.6 LNs (median 20, SD 9) per
operation. Metastases were found in 183 (18.8 %) of 971
removed LNs. The mean number of positive LNs per pa-
tient was 4.1 (Table 2). In 22 patients (48.9 %, 95 % CI:
35.8–62.1 %) >20 LNs were removed per operation. In
26 patients (57.8 %, 95 % CI: 44.3–70.4 %), N1 stage was
histologically confirmed. In four patients (8.9 %, 95 %
CI: 3.7–18.3 %), just one LN was positive; in two pa-
tients (4.4 %, 95 % CI: 1.4–11.8 %) two LNs were posi-
tive; in 12 patients (26.7 %, 95 % CI: 16.4–39.5 %) 3–5
LNs were positive; in three patients (6.7 %, 95 % CI: 2.5–
15.1 %) 6–10 LNs were positive; and in five patients
(11.1 %, 95 % CI: 5.1–21.2 %) >10 LNs were positive
(Table 3).
We have divided the patients into subgroups differen-
tiating between pre- and postoperative ADT receivers
and non-receivers and their post-operative ADT-
response in Table 4.
Table 2 Summary of results of salvage treatment (n = 45)
Follow-up (months), mean (SD) 42.7 (±20.8)
Median PSA-nadir after salvage ePLND, ng/ml (SD) 4.4 ± 1.5
N-stage after salvage ePLND
N0 (%) 19 (42.2 %)
N1 (%) 26 (58.7 %)
No. of LNs removed (range) 971 (4–76)
Mean no. of LNs removed per patient (SD) 21.6 (±9)
No. of positive LNs (range) 183 (1–42)
No. of positive LNs per patient (range) 4,1 (1–42)
No. of deaths (%) 7 (15.6 %)
Time to death (months), mean (range) 48.8 5–105
BR after salvage ePLND n (% patients) 31 (68.9 %)
BCRF immediately after salvage ePLND
(complete BR) n (% patients)
22 (48.9 %)
BCRF during follow-up n (% patients) 33 (73.3 %)
Mean BCRF duration (months) (SD) 31.4 (±19.7)
ADT before salvage ePLND
No. (%) patients
36 (80.0 %)
ADT after salvage ePLND
No. (%) patients
40 (88.9 %)
Bone metastases in follow-up after salvage ePLND
No. (%) patients
10 (22.2 %)
Biochemical recurrence-free survival in patients after salvage ePLND (n=45)
n=26 number of events n=19 number at risk







































Fig. 1 Biochemical recurrence-free survival in patients after salvage ePLND (n = 45)
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The following complications were observed in seven
patients (15.6 %, 95 % CI: 8.0–26.8 %); all related to
Grade IIIb Clavien–Dindo complications: two patients
(4.4 %, 95 % CI: 1.4–11.8 %) with postoperative rele-
vant bleeding: two (4.4 %, 95 % CI: 1.4–11.8 %) with
ureteral stricture; one with rectovesical fistula (2.2 %,
95 % CI: 0.5–7.9 %), and two (4.4 %, 95 % CI: 1.4–
11.8 %) with lymphocele.
We analyzed the risk factors for cancer-specific mor-
tality. Only the occurrence of bone metastases during
follow-up after salvage ePLND was shown to be a sig-
nificant risk factor (Table 5).
Discussion
According to our results, we cannot postulate any bene-
fit of salvage ePLND because of the limitation of the
study, in particular its’ small retrospective character and
heavily selected cohort of patients. Despite of that, the
results have showed, that in the majority of patients
BCRF were achieved, even in those with no histologically
Biochemical recurrence-free survival in patients after salvage ePLND 
(n=45) comparing patients with (n=10) and without (n=35) bone
metastases
n=26 number of events n=19 number at risk
without BM (n=35)
with BM (n=10)







































Fig. 2 Biochemical recurrence-free survival in patients after salvage ePLND (n = 45) comparing patients with (n = 10) and without (n = 35)
bone metastases
Cancer specific survival in patients after salvage ePLND (n=45)
n=6 number of events n=39 number at risk
































Fig. 3 Cancer specific survival in patients after salvage ePLND (n = 45)
Osmonov et al. BMC Urology  (2016) 16:56 Page 5 of 9
proven LN metastases. Moreover, CSS and OS data
compared with acceptable complications rate makes this
procedure feasible for selected patients. Similar results
were found in previous studies on salvage ePLND. Thus,
the data collected in different centers demonstrate com-
parable results [15] The most important two parameters
are (1) complete biochemical response within 40 d after
surgery (range: 46 %; 48.9 % up to 56.9 %) and (2)
achievement of BCR-freedom after salvage ePLND with
rates of up to 71.8 %. The role of ADT after salvage sur-
gery remains a critical and unresolved issue, however.
The retrospective character of the study does not provide
us with the opportunity to divide the patients into different
groups with and without ADT. Moreover, the concept of re-
current PCa salvage treatment makes it impossible to split
salvage ePLND and ADT; both treatments can and should
be used in a combined approach. This approach has allowed
us and other centers to achieve similarly high rates of CSS
ranging between 75 % and 80.6 % [15].
We believe that the aim of any further research is to
demonstrate that patients benefit from salvage ePLND. The
selection of patients, taking into consideration the above-
shown absence of reliable LN recurrence imaging tools, re-
mains a matter of dispute.
13 (68.4 %) of 19 node-negative patients showed a BR im-
mediately after salvage ePLND. 16 (84.2 %) reached BCRF
during postoperative follow-up with a mean duration
of 33 ± 22 months, median 28.5 (min 6 – max 81)
months. However, 17 (89.5 %) undergone ADT after
salvage ePLND in follow-up.
Again, 84.2 % patients with stage N0 after salvage sur-
gery were BCR free. We discussed possible explanations
for this with our pathologist and during various inter-
national meetings. For a better understanding, we also
need to consider the method of pathological examination.
Pathological examination of removed LNs may miss
micrometastases, which are defined in different ways de-
pending on the cancer entity. In malignant melanoma,
for example, one isolated tumor cell is already consid-
ered a micrometastasis according to the American Joint
Committee on Cancer, although it can only be detected
by means of immunohistochemistry. In breast cancer,
micrometastases are defined as >200 μm (and/or >200
tumor cells) and <2 mm in diameter. Such micrometas-
tases can be detected by light microscopy. In penile can-
cer, a micrometastasis is defined as being <2 mm [16].
There is no clear definition of micrometastasis with re-
spect to PCa or cancer of other parenchymal organs.
The International Society of Urological Pathology has no
consensus on the definition of micrometastasis in PCa
[17]. The problem is that something that is not clearly
defined cannot be found.
However, we believe that we did remove LNs carrying
micrometastases or even true metastases that were
Overall survival in patients after salvage ePLND (n=45)
n=7 number of events n=38 number at risk


























Fig. 4 Overall survival in patients after salvage ePLND (n = 45)
Table 3 Number of positive LNs per patient
No. of patients Positive LNs per patient
19 (42.2 %) Node-negative (N0)
4 (8.9 %) 1 LN+
2 (4.4 %) 2 LNs+
12 (26.7 %) 3-5 LNs+
3 (6.7 %) 6-10 LNs+
5 (11.1 %) >10 LNs+
Summary: 45 patients Mean LN+ pro patient 4.1 (range 1–42)
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missed using the applied pathological method. We sys-
tematically removed all potentially positive LNs from
various areas following the Kiel surgical template of sal-
vage ePLND [14]. Most of the positive LNs were found
in the area of the common iliac artery (37.5 %), paraaor-
tal area (20 %), sacral area (12.5 %), and in the area of
the triangle of Marcille (5 %). This is an important argu-
ment in favor of template-oriented surgery rather than
selective or limited LN removal.
The small number of studies [15] shows the outcome of
salvage ePLND, but it is more difficult to assess the differ-
ence in survival of patients after salvage ePLND alone
versus patients after salvage ePLND and adjuvant
ADT. In addition, it is difficult to assess the
independent impact of these two therapeutic measures on
progression-free survival. We observed an interesting
phenomenon: in patients with CRPC and BCR, ADT can
be effective again after salvage ePLND. We reported this
side effect of salvage surgery at the 2014 meetings of the
German Society of Urology, EAU and American Uro-
logical Association. This effect was detected after analys-
ing all data and is a largely unexpected result of our study.
We describe this effect with caution and as a preliminary
statement. Moreover, we still lack an adequate explanation
for this effect. However, we believe that this finding will
have a major impact on the role of salvage ePLND if our
data are confirmed by other study groups, ideally in a pro-
spective setup with larger patient cohorts and in multicen-
ter trials.
Our hypothesis so far is based on the tumor biol-
ogy of PCa. The PCa tumor architecture is heteroge-
neous and probably depends on the different c-types
and their mutation characteristics. There are a few
theories about this heterogeneity, which can have an
impact on the aggressiveness and speed of metastatic
spread. In breast cancer, for example, the BRCA-1
and BRCA-2 genes indicate a strong dependency be-
tween BRCA-gene types and lymphatic and hemato-
geneous metastatic spread [18]. These two genes are
found in LN or organ metastases of PCa. However,
we believe that heterogeneity in PCa metastasis is
even more complex. Based on the described facts,
we see the potential reason for the renewed ADT re-
sponse as the removal of aggressive tumor cells,
which are probably chiefly responsible for metastatic
spread of the tumor.
Table 4 BCRF-survival in subgroups of patients according to pre- and postoperative ADT receivers and non-receivers and their post-
operative ADT-response
Without ADT after surgery With ADT after surgery
Patients without
preoperative ADT, n = 9 (20 %)
Total without / with ADT 3 (33.3 %) 6 (66.7 %)
Of the above: BCRF-survival






after salvage ePLND (months):
1. mean duration ± SD
18 ± 3 33.4 ± 15.8
2. median duration 18 36
3. min-max duration 15–21 6–53
Patients with preoperative
ADT n = 36 (80 %)
Total without / with ADT 2 (5.6 %) 34 (94.4 %)
Of the above: BCRF-survival






after salvage ePLND (months):
1. mean duration ± SD
54.5 ± 5.5 30.1 ± 25.2
2. median duration 51.75 23.5
3. min-max duration 49–60 4–93
Table 5 Risk factors of cancer-specific mortality (univariate
analysis)
Risk factor (CSS) p (significance)
Decrease of PSA level after salvage ePLND 0.268





Number of LNs 0.296
No. of LNs removed 0.42
Risk-group (D’Amico) 0.619
Bone metastases at follow-up <0.001
Age at moment of salvage ePLND 0.249
Surgical complications 0.745
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The interest in lesion-targeted salvage therapies
has increased recently [19]. The outcome of salvage
surgery and other diagnostic methods for positive
LN detection compared to pathological examination
needs to be evaluated further. Moreover, salvage sur-
gery needs to be included in PCa guidelines. Lesion-
targeted or selective salvage PLND can only be en-
hanced with development of new diagnostic imaging.
Some recent studies have shown promising results
with Ga-PSMA (68Gallium- Prostate-specific mem-
brane antigen) PET/magnetic resonance imaging
(MRI) and Ga-PSMA PET/CT [20, 21].
Most of the studies describing the clinical outcome of
salvage ePLND are based on the findings of 18F choline
PET/CT findings. Application of the tracer 18F-2-fluoro-
2-deoxyglucose in PET/CT is successfully used in many
tumor types. However, a benefit in PCa diagnosis has
been questioned by several authors [22, 23].
There have been divergent results on choline-PET/
CT regarding PCa recurrence. In several studies the
detection rates were analyzed in relation to the PSA
level. These studies have shown the sensitivity of
choline-PET/CT for detection of LN metastases to be
as low as 41.1 % [24]. Therefore, extensive salvage
treatment is needed to maximize the chance of cure
[19]. However, these results are insufficient to
standardize the indications for salvage ePLND.
Data from our own department show a low specifi-
city of 18.2 % with a relatively satisfactory sensitivity
of 85.2 %. Most importantly, the positive predictive
value and negative predictive value were 56.1 % and
50.0 %, respectively [25]. Therefore, we conclude that
the reliability of PET/CT imaging for detection of LN
metastases is limited by a high false-positive rate, and
the findings in patients with low PSA values were as-
sociated with a high ratio of errors. In this situation,
there is still no alternative to the template-based sal-
vage ePLND to remove all LNs and thus to detect all
metastatic LNs, including those that were false nega-
tive by PET/CT.
Here, as well as in the validation of the method men-
tioned above, a prospective study design should be set up
for a full analysis of false-positive and false-negative results
regarding LN metastasis. This will only be possible if histo-
logical verification is done after template-based ePLND.
Looking at the largest studies in this field, the CSS
results in patients who underwent salvage ePLND
seem to be similar despite the different cohorts ana-
lyzed by different workgroups. Thus, Jilg et al. re-
ported 5-years CSS of 77.7 %, Rigatti et.al – 75 %,
and our current data show 80.6 % [9, 10].
In the absence of evidence-based guidelines regarding
salvage ePLND, our study and the publications listed in
Table 1 allow us to conclude that salvage ePLND is
effective and useful in selected patients. The only statisti-
cally significant finding in this study is that bone metasta-
sis is associated with more rapid mortality. This is an
important point which can help us define the indication
criteria for salvage ePLND, but it should not be used to
question the clinical significance of salvage surgery.
The requirements placed on the surgeon are high,
however. The current situation remains unsatisfactory
due to the lack of prospective multicenter randomized
studies. We concede that our study was only a retro-
spective analysis. However, there are two good rea-
sons for publishing these data. First, we needed to
evaluate our own patient data in order to decide
whether we can go further with salvage ePLND as a
treatment option. Second, this analysis will serve as a
basis for a prospective trial, for example, by joining in
the SALPRO study of our colleagues from Freiburg,
Germany. Finally, the low rate of complications that
we found justifies further pursuit of this strategy.
Conclusion
Salvage ePLND resulted in an immediate complete PSA
response in nearly 50 % of the patients and in a BR in
more than two-thirds. CSS and OS were equal at 91.7 ±
4.8 % (3-year CSS and OS) and 80.6 ± 8.6 % (5-year CSS
and OS). In addition, one of the most important results
of our study was the fact that 53.3 % of previous CRPC
patients respond to ADT again after salvage ePLND.
Bone metastasis is a poor prognostic surveillance factor
after salvage ePLND. We do not wish to suggest that sal-
vage surgery should be performed in patients with bone
metastases, but we believe that salvage ePLND should
find a place in the guidelines for selected groups of pa-
tients, especially as an additional option for CRPC pa-
tients. Multicenter prospective studies with control
groups are needed to achieve a reliable output.
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